Yuehua Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuehua Han has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Peiwei Li
Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang University School of Medicine
3 shared publicationsCheng Fang
Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang University School of Medicine
2 shared publicationsQin Du
Department of Gastroenterology Second Affiliated Hospital, Zhejiang University College of Medicine Hangzhou China
2 shared publicationsYan Chen
Department of Gastroenterology Second Affiliated Hospital, Zhejiang University College of Medicine Hangzhou China
2 shared publicationsYan Li
Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang University School of Medicine
2 shared publicationsChunpeng Zhu
1 shared publication
Latest Publications
- Open Access
Post-Translational Modification Crosstalk in Gastric Cancer: Molecular Switches, Signaling Networks, and Therapeutic Opportunities, with Comparative Insights from Colorectal Cancer
Gastric cancer remains a leading cause of cancer-related death, and its malignant behavior is driven in large part by dysregulated post-translational modifications (PTMs). Yet the prevailing tendency to study individual modifications in isolation has obscured a defining feature of PTM biology: modifications frequently interact, competing for the same residue or cooperating across residues to form regulatory switches that dictate protein fate. This review synthesizes the PTM crosstalk framework in gastric cancer around three principal axes—phosphorylation–ubiquitination relays, SUMOylation–ubiquitination interplay, and metabolic coupling through lactylation—and traces how these axes translate into the hallmarks of proliferation, metastasis, therapeutic resistance, and immune evasion. The framework is further extended to colorectal cancer to separate shared regulatory principles from cancer-specific switches. Central to this account is the proposition that oncogenic output is governed not by any single modification but by the balance among competing and cooperating marks, and that the switch enzymes maintaining this balance constitute the most informative therapeutic targets. Translating this view into therapy will require selective degraders and inhibitors, crosstalk-aware biomarkers, and systematic multi-omics maps of the modification network.
Open AccessPost-Translational Modification Crosstalk in Gastric Cancer: Molecular Switches, Signaling Networks, and Therapeutic Opportunities, with Comparative Insights from Colorectal Cancer
Gastric cancer remains a leading cause of cancer-related death, and its malignant behavior is driven in large part by dysregulated post-translational modifications (PTMs). Yet the prevailing tendency to study individual modifications in isolation has obscured a defining feature of PTM biology: modifications frequently interact, competing for the same residue or cooperating across residues to form regulatory switches that dictate protein fate. This review synthesizes the PTM crosstalk framework in gastric cancer around three principal axes—phosphorylation–ubiquitination relays, SUMOylation–ubiquitination interplay, and metabolic coupling through lactylation—and traces how these axes translate into the hallmarks of proliferation, metastasis, therapeutic resistance, and immune evasion. The framework is further extended to colorectal cancer to separate shared regulatory principles from cancer-specific switches. Central to this account is the proposition that oncogenic output is governed not by any single modification but by the balance among competing and cooperating marks, and that the switch enzymes maintaining this balance constitute the most informative therapeutic targets. Translating this view into therapy will require selective degraders and inhibitors, crosstalk-aware biomarkers, and systematic multi-omics maps of the modification network.
- Open Access
- 20 May 2026
- Published by Elsevier in SSRN Electronic Journal
New Insights of Gut Microbiota Beyond H. pylori In Gastric Precancerous Disease and Its Correlation with Gastric Carcinogenesis
Gastric cancer (GC) is one of the most common malignancies and a prominent cause of cancer mortality worldwide. H. pylori infection promotes atrophy, IM and GC. Nevertheless, the identification and characterization of non-H. pylori driver bacteria associated with gastric carcinogenesis remain unexplored. In our study, we characterized the fecal microbial composition and mucosal metabolites in patients with progressive histological stages along gastric tumorigenesis—from SG through AG to GC. Interestingly, the abundance of S. anginosus was increased in the GC group when compared to both SG and AG groups. In the while, the GC group harbored a higher level of P. merdae and B. bifidum compared to the AG group. The abundance of P. merdae distinguished the GC and SG group, the area under the curve (AUC) was 0.6963. Furthermore, non-targeted metabolomics found the lyso family including lysoPC, lysoPS and lysoPE increased in the tumor tissue. The PldA enzyme was the key enzyme combination the phospholipids, and we found P. merdae held the genome of PldA enzyme. This study suggests the level of P. merdae might be a biomarker in monitoring the progression of GC.
- 20 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNew Insights of Gut Microbiota Beyond H. pylori In Gastric Precancerous Disease and Its Correlation with Gastric Carcinogenesis
Gastric cancer (GC) is one of the most common malignancies and a prominent cause of cancer mortality worldwide. H. pylori infection promotes atrophy, IM and GC. Nevertheless, the identification and characterization of non-H. pylori driver bacteria associated with gastric carcinogenesis remain unexplored. In our study, we characterized the fecal microbial composition and mucosal metabolites in patients with progressive histological stages along gastric tumorigenesis—from SG through AG to GC. Interestingly, the abundance of S. anginosus was increased in the GC group when compared to both SG and AG groups. In the while, the GC group harbored a higher level of P. merdae and B. bifidum compared to the AG group. The abundance of P. merdae distinguished the GC and SG group, the area under the curve (AUC) was 0.6963. Furthermore, non-targeted metabolomics found the lyso family including lysoPC, lysoPS and lysoPE increased in the tumor tissue. The PldA enzyme was the key enzyme combination the phospholipids, and we found P. merdae held the genome of PldA enzyme. This study suggests the level of P. merdae might be a biomarker in monitoring the progression of GC.
- Open Access
- 13 April 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1811628
Monoclonal stool antigen test for diagnosing Helicobacter pylori in chronic atrophic gastritis: a prospective primary care study
Background/aims: Diagnosing active Helicobacter pylori ( H. pylori ) infection in patients with chronic atrophic gastritis (CAG) remains challenging. The monoclonal stool antigen test (SAT) offers a non-invasive alternative to endoscopic methods. This study aimed to evaluate the diagnostic accuracy of SAT in CAG and to analyze its performance in relation to the severity of gastric atrophy. Methods: In this prospective study, 287 patients with CAG underwent SAT, urea breath test, serology, and histology. Patients were stratified into low-risk and high-risk groups based on gastric cancer progression risk. SAT was assessed against a reference standard combining histology and UBT. Results: The area under the ROC curve for SAT was 0.858. SAT showed a sensitivity of 75.9% and a specificity of 96.1%. In high-risk patients, SAT demonstrated comparable specificity (96.77% vs. 95.77%) and positive predictive value (95.24% vs. 93.48%) to those in low-risk patients, with numerically higher accuracy (89.29% vs. 86.05%). Consistency analysis revealed substantial agreement between SAT and the reference standard overall (κ=0.72), with stronger agreement in the high-risk patients (κ=0.77) than in the low-risk patients (κ=0.69). Conclusions: Monoclonal SAT is a reliable non-invasive tool for detecting H. pylori in CAG, exhibiting high specificity and strong diagnostic consistency. Its performance is positively correlated with the severity of gastric atrophy, supporting its preferential use in high-risk, advanced atrophy populations.
- 13 April 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1811628
Open AccessMonoclonal stool antigen test for diagnosing Helicobacter pylori in chronic atrophic gastritis: a prospective primary care study
Background/aims: Diagnosing active Helicobacter pylori ( H. pylori ) infection in patients with chronic atrophic gastritis (CAG) remains challenging. The monoclonal stool antigen test (SAT) offers a non-invasive alternative to endoscopic methods. This study aimed to evaluate the diagnostic accuracy of SAT in CAG and to analyze its performance in relation to the severity of gastric atrophy. Methods: In this prospective study, 287 patients with CAG underwent SAT, urea breath test, serology, and histology. Patients were stratified into low-risk and high-risk groups based on gastric cancer progression risk. SAT was assessed against a reference standard combining histology and UBT. Results: The area under the ROC curve for SAT was 0.858. SAT showed a sensitivity of 75.9% and a specificity of 96.1%. In high-risk patients, SAT demonstrated comparable specificity (96.77% vs. 95.77%) and positive predictive value (95.24% vs. 93.48%) to those in low-risk patients, with numerically higher accuracy (89.29% vs. 86.05%). Consistency analysis revealed substantial agreement between SAT and the reference standard overall (κ=0.72), with stronger agreement in the high-risk patients (κ=0.77) than in the low-risk patients (κ=0.69). Conclusions: Monoclonal SAT is a reliable non-invasive tool for detecting H. pylori in CAG, exhibiting high specificity and strong diagnostic consistency. Its performance is positively correlated with the severity of gastric atrophy, supporting its preferential use in high-risk, advanced atrophy populations.
- Open Access
Efficacy and Safety of 10‐Day Minocycline Twice Daily in Bismuth‐Containing Quadruple Therapy as the First‐Line Treatment of Helicobacter pylori Infection: A Prospective Single‐Arm Study
Background: Tetracycline has limited clinical application in Helicobacter pylori treatment because of difficulty in obtaining and increased adverse reactions. As a semisynthetic tetracycline, minocycline has demonstrated good potential for eradicating H. pylori infection. This study aimed to evaluate the efficacy and safety of 10‐day minocycline‐based quadruple therapy for H. pylori first‐line treatment.Methods: In this prospective trial, treatment‐naïve adults with H. pylori infection received eradication therapy with rabeprazole 10 mg, minocycline 100 mg, amoxicillin 1000 mg, and bismuth potassium citrate 220 mg each given twice a day for 10 days. The primary outcome was the eradication rate. The secondary outcome was adverse effects. Eradication was confirmed by a negative urea breath test at least 6 weeks after the end of therapy.Results: A total of 133 patients were included in the study. All of the patients completed the course of medication. We found that 10‐day minocycline‐amoxicillin quadruple therapy achieved an eradication rate of 83.5% (111/133, 95% CI 80.3%–86.7%) in intention‐to‐treat analysis and 90.2% (111/123, 95% CI 87.6%–92.8%) in per‐protocol analysis. The treatment‐emergent adverse events (TEAEs) were 15% (20/133), with the most common adverse event being dizziness (14/133, 10.5%). No severe adverse event was observed.Conclusions: Ten‐day minocycline‐amoxicillin twice daily in bismuth‐containing quadruple therapy appears to be effective and safe for naïve H. pylori patients.
Open AccessEfficacy and Safety of 10‐Day Minocycline Twice Daily in Bismuth‐Containing Quadruple Therapy as the First‐Line Treatment of Helicobacter pylori Infection: A Prospective Single‐Arm Study
Background: Tetracycline has limited clinical application in Helicobacter pylori treatment because of difficulty in obtaining and increased adverse reactions. As a semisynthetic tetracycline, minocycline has demonstrated good potential for eradicating H. pylori infection. This study aimed to evaluate the efficacy and safety of 10‐day minocycline‐based quadruple therapy for H. pylori first‐line treatment.Methods: In this prospective trial, treatment‐naïve adults with H. pylori infection received eradication therapy with rabeprazole 10 mg, minocycline 100 mg, amoxicillin 1000 mg, and bismuth potassium citrate 220 mg each given twice a day for 10 days. The primary outcome was the eradication rate. The secondary outcome was adverse effects. Eradication was confirmed by a negative urea breath test at least 6 weeks after the end of therapy.Results: A total of 133 patients were included in the study. All of the patients completed the course of medication. We found that 10‐day minocycline‐amoxicillin quadruple therapy achieved an eradication rate of 83.5% (111/133, 95% CI 80.3%–86.7%) in intention‐to‐treat analysis and 90.2% (111/123, 95% CI 87.6%–92.8%) in per‐protocol analysis. The treatment‐emergent adverse events (TEAEs) were 15% (20/133), with the most common adverse event being dizziness (14/133, 10.5%). No severe adverse event was observed.Conclusions: Ten‐day minocycline‐amoxicillin twice daily in bismuth‐containing quadruple therapy appears to be effective and safe for naïve H. pylori patients.
- Open Access
- 15 May 2025
- Published by MDPI AG in Journal of Imaging
- Vol. 11 (5) , 154
A Multitask Network for the Diagnosis of Autoimmune Gastritis
Autoimmune gastritis (AIG) has a strong correlation with gastric neuroendocrine tumors (NETs) and gastric cancer, making its timely and accurate diagnosis crucial for tumor prevention. The endoscopic manifestations of AIG differ from those of gastritis caused by Helicobacter pylori (H. pylori) infection in terms of the affected gastric anatomical regions and the pathological characteristics observed in biopsy samples. Therefore, when diagnosing AIG based on endoscopic images, it is essential not only to distinguish between normal and atrophic gastric mucosa but also to accurately identify the anatomical region in which the atrophic mucosa is located. In this study, we propose a patient-based multitask gastroscopy image classification network that analyzes all images obtained during the endoscopic procedure. First, we employ the Scale-Invariant Feature Transform (SIFT) algorithm for image registration, generating an image similarity matrix. Next, we use a hierarchical clustering algorithm to group images based on this matrix. Finally, we apply the RepLKNet model, which utilizes large-kernel convolution, to each image group to perform two tasks: anatomical region classification and lesion recognition. Our method achieves an accuracy of 93.4 ± 0.5% (95% CI) and a precision of 92.6 ± 0.4% (95% CI) in the anatomical region classification task, which categorizes images into the fundus, body, and antrum. Additionally, it attains an accuracy of 90.2 ± 1.0% (95% CI) and a precision of 90.5 ± 0.8% (95% CI) in the lesion recognition task, which identifies the presence of gastric mucosal atrophic lesions in gastroscopy images. These results demonstrate that the proposed multitask patient-based gastroscopy image analysis method holds significant practical value for advancing computer-aided diagnosis systems for atrophic gastritis and enhancing the diagnostic accuracy and efficiency of AIG.
- 15 May 2025
- Published by MDPI AG in Journal of Imaging
- Vol. 11 (5) , 154
Open AccessA Multitask Network for the Diagnosis of Autoimmune Gastritis
Autoimmune gastritis (AIG) has a strong correlation with gastric neuroendocrine tumors (NETs) and gastric cancer, making its timely and accurate diagnosis crucial for tumor prevention. The endoscopic manifestations of AIG differ from those of gastritis caused by Helicobacter pylori (H. pylori) infection in terms of the affected gastric anatomical regions and the pathological characteristics observed in biopsy samples. Therefore, when diagnosing AIG based on endoscopic images, it is essential not only to distinguish between normal and atrophic gastric mucosa but also to accurately identify the anatomical region in which the atrophic mucosa is located. In this study, we propose a patient-based multitask gastroscopy image classification network that analyzes all images obtained during the endoscopic procedure. First, we employ the Scale-Invariant Feature Transform (SIFT) algorithm for image registration, generating an image similarity matrix. Next, we use a hierarchical clustering algorithm to group images based on this matrix. Finally, we apply the RepLKNet model, which utilizes large-kernel convolution, to each image group to perform two tasks: anatomical region classification and lesion recognition. Our method achieves an accuracy of 93.4 ± 0.5% (95% CI) and a precision of 92.6 ± 0.4% (95% CI) in the anatomical region classification task, which categorizes images into the fundus, body, and antrum. Additionally, it attains an accuracy of 90.2 ± 1.0% (95% CI) and a precision of 90.5 ± 0.8% (95% CI) in the lesion recognition task, which identifies the presence of gastric mucosal atrophic lesions in gastroscopy images. These results demonstrate that the proposed multitask patient-based gastroscopy image analysis method holds significant practical value for advancing computer-aided diagnosis systems for atrophic gastritis and enhancing the diagnostic accuracy and efficiency of AIG.
- Open Access
- 7 September 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 973975
Susceptibility-guided vs. empirical 10-day quadruple treatment for Helicobacter pylori-infected patients: A prospective clinical trial of first-line therapy
Background: The increasing antimicrobial resistance of Helicobacter pylori (H. pylori) has resulted in a fall in cure rates. We aimed to assess the effectiveness of first-line susceptibility-guided therapy and furazolidone-based quadruple therapy for H. pylori-infected patients.Methods: Subjects with H. pylori-infection were randomly assigned to either 10-day susceptibility-guided treatment or empiric treatment in a 2:1 ratio. Susceptibility-guided therapy was based on susceptibility to clarithromycin, and patients with susceptible strains received clarithromycin 500 mg twice daily and otherwise minocycline 100 mg twice a day was administered. Patients in the empiric therapy group was treated with furazolidone 100 mg twice a day. During treatment, all patients were given esomeprazole 20 mg twice daily, colloidal bismuth pectin 200 mg twice daily, and amoxicillin 1 g twice daily.Results: A total of 248 patients were screened and 201 were finally included. Empiric and susceptibility-guided regimens were both successful with per-protocol eradication rates of 90.5% (57/63) vs. 88.5% (108/122) (p = 0.685) and intent-to-treat eradication rates of 85.1% (57/67) vs. 80.6% (108/134) (p = 0.435). No significant difference in eradication rates were observed among the furazolidone group, clarithromycin group and minocycline group.Conclusion: Both susceptibility-guided therapy and quadruple therapy containing furazolidone can achieve good eradication rates. For population with a high rate of resistance, quadruple therapy containing furazolidone and bismuth may be a more practical choice for first-line treatment.
- 7 September 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 973975
Open AccessSusceptibility-guided vs. empirical 10-day quadruple treatment for Helicobacter pylori-infected patients: A prospective clinical trial of first-line therapy
Background: The increasing antimicrobial resistance of Helicobacter pylori (H. pylori) has resulted in a fall in cure rates. We aimed to assess the effectiveness of first-line susceptibility-guided therapy and furazolidone-based quadruple therapy for H. pylori-infected patients.Methods: Subjects with H. pylori-infection were randomly assigned to either 10-day susceptibility-guided treatment or empiric treatment in a 2:1 ratio. Susceptibility-guided therapy was based on susceptibility to clarithromycin, and patients with susceptible strains received clarithromycin 500 mg twice daily and otherwise minocycline 100 mg twice a day was administered. Patients in the empiric therapy group was treated with furazolidone 100 mg twice a day. During treatment, all patients were given esomeprazole 20 mg twice daily, colloidal bismuth pectin 200 mg twice daily, and amoxicillin 1 g twice daily.Results: A total of 248 patients were screened and 201 were finally included. Empiric and susceptibility-guided regimens were both successful with per-protocol eradication rates of 90.5% (57/63) vs. 88.5% (108/122) (p = 0.685) and intent-to-treat eradication rates of 85.1% (57/67) vs. 80.6% (108/134) (p = 0.435). No significant difference in eradication rates were observed among the furazolidone group, clarithromycin group and minocycline group.Conclusion: Both susceptibility-guided therapy and quadruple therapy containing furazolidone can achieve good eradication rates. For population with a high rate of resistance, quadruple therapy containing furazolidone and bismuth may be a more practical choice for first-line treatment.